Camurus AB (LTS:0RD1) ROCE % : -4.62% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Camurus AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Camurus AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -4.62%.

Camurus AB ROCE % Historical Data

The historical data trend for Camurus AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB ROCE % Chart

Camurus AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-79.39

-26.94

-12.71

7.86

42.96

Camurus AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															8.20	29.26	121.69	29.87	-4.62

Camurus AB ROCE % Calculation

Camurus AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	550.579	/	( ( (1305.488 - 281.642)	+	(1907.82 - 368.594) )	/ 2 )
	=	550.579	/	( (1023.846	+	1539.226)	/ 2 )
	=	550.579	/	1281.536
	=	42.96 %

Camurus AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-70.896	/	( ( (1841.665 - 309.62)	+	(1907.82 - 368.594) )	/ 2 )
	=	-70.896	/	( ( 1532.045	+	1539.226 )	/ 2 )
	=	-70.896	/	1535.6355
	=	-4.62 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Camurus AB (LTS:0RD1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Camurus AB ROCE % Related Terms

Thank you for viewing the detailed overview of Camurus AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Camurus AB (LTS:0RD1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (LTS:0RD1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CAMX:Sweden 7CA:Germany

Address

Ideon Science Park, Lund, SWE, SE-223 70

Website

https://www.camurus.com

Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The company's product pipeline includes CAM2038, CAM2029, CAM2032, and others. The company's geographical revenue includes Europe (of which Sweden), the United States of America, Australia, and Other geographical areas.

Camurus AB (LTS:0RD1) Headlines

No Headlines